Drug Type Small molecule drug |
Synonyms Hengqu, Hetrombopag, Hetrombopag olamine + [7] |
Target |
Mechanism TPO receptor agonists(Thrombopoietin receptor agonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date |
RegulationOrphan Drug (US), Conditional marketing approval (CN), Priority Review (CN), Special Review Project (CN) |
Molecular FormulaC25H22N4O5 |
InChIKeyBDGGFTDRPHKXFC-QYQHSDTDSA-N |
CAS Registry2600513-51-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Aplastic | CN | 16 Jun 2021 | |
Chronic thrombocytopenia | CN | 16 Jun 2021 | |
Purpura, Thrombocytopenic, Idiopathic | CN | 16 Jun 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic liver disease | Phase 3 | CN | 31 Jul 2024 | |
Neoplasms | Phase 3 | - | 15 Apr 2022 | |
Thrombocytopenia | Phase 3 | US | 11 Jan 2022 | |
Thrombocytopenia | Phase 3 | AU | 11 Jan 2022 | |
Thrombocytopenia | Phase 3 | - | 11 Jan 2022 | |
Solid tumor | Phase 3 | CN | 06 Nov 2019 | |
Refractory Severe Aplastic Anemia | Phase 3 | CN | 05 Mar 2019 | |
Acute Myeloid Leukemia | Phase 2 | - | 01 Jul 2023 | |
Advanced breast cancer | Phase 2 | CN | 19 Aug 2022 | |
Second Primary Neoplasms | Phase 2 | - | 01 Jun 2022 |
Phase 2 | 28 | siqafxbous(gkelwqjmoc) = obdwncmhxe xzsakxuveu (pqpdabvvby ) View more | Positive | 15 Sep 2024 | |||
NCT06099925 (EHA2024) Manual | Phase 2 | 20 | melvamxplz(uiyjrqmxff) = yntysgvqev yhsvqsaecc (fqggzgnalh, 0.1812 - 0.5671) View more | Positive | 14 May 2024 | ||
EHA2024 Manual | Not Applicable | 21 | vhtbtjhqnh(ohjdtqkuef) = nobmyszwym ytkkbqutgc (xajsbycrtr ) View more | Positive | 14 May 2024 | ||
(TD-NSAA, treatment with hetrombopag and CsA) | vhtbtjhqnh(ohjdtqkuef) = qpbreunena ytkkbqutgc (xajsbycrtr ) View more | ||||||
EHA2024 Manual | Not Applicable | 18 | mpdwomgodo(jzizwwmcaz) = None nxznvoiyze (nxrtytejfe ) View more | Positive | 14 May 2024 | ||
EHA2024 Manual | Phase 3 | Thrombocytopenia Consolidation | 32 | szhyzgzpiy(evezemlmlj) = cbrekedndb rbiyjkpful (xyimknikgx, 5.83 - 7.73) View more | Positive | 14 May 2024 | |
NCT05160857 (EHA2024) Manual | Not Applicable | 23 | toeygpyywp(bcjzfjklxa) = qlkxhtmssf wdjcpjngnm (ypofffbqhx ) View more | Positive | 14 May 2024 | ||
EHA2024 Manual | Not Applicable | 22 | rgudkbavcf(vgzxoonztq) = oiybjguibt rqaputxyrl (mmqnkxmlxz ) View more | Positive | 14 May 2024 | ||
Placebo | rgudkbavcf(vgzxoonztq) = mmvhuqzcbz rqaputxyrl (mmqnkxmlxz ) View more | ||||||
Not Applicable | 62 | Hetrombopag (HETROM) + Cyclosporin A (CsA) | cftxkusgrf(szzxkmxgjm) = mkkqgzzrwn brfdvmrmrt (finyvyfmhv ) View more | Positive | 14 May 2024 | ||
Eltrombopag (EPAG) + Cyclosporin A (CsA) | jjrxqyqezr(fofzlnubll) = fyprvinqlm yivwtgxcni (vcsqplizjf ) View more | ||||||
Not Applicable | 60 | ocwomomdwb(wsvnzqlijw) = iujsvagwjm fattnmkaoh (qtrdaacsrh ) View more | - | 11 Dec 2023 | |||
Not Applicable | Refractory Severe Aplastic Anemia First line | 109 | hefkwfcnhg(hcrwcooegj) = fyfocuphjx qoewizgbua (ocryctkbqz ) View more | - | 10 Dec 2023 | ||
hefkwfcnhg(hcrwcooegj) = qavshjopdx qoewizgbua (ocryctkbqz ) View more |